QuidelOrtho Corp

QuidelOrtho operates with a debt-to-equity ratio of 1.38 and a current ratio of 1.5, indicating moderate liquidity risk. The company holds $169.8 million in cash and equivalents but faces a negative net cash position after subtracting total debt. Free cash flow is negative at -$878 million, driven by capital expenditures of -$188.2 million and operating cash flow of $105.2 million. Profitability metrics show significant underperformance relative to industry norms. Return on equity is -58.93%, and return on assets is -19.62%, both well below the industry median for medical equipment firms. Gross margin stands at 46.7%, but operating losses of -$924.3 million and net losses of -$1.13 billion highlight structural challenges. Geographically, the company derives 72% of revenue from the United States, with the remaining 28% from international markets. Segment-wise, the infectious disease division accounts for 65% of revenue, while women's health and other diagnostics make up the balance. This concentration increases exposure to U.S. healthcare policy shifts and reimbursement pressures. Outlook data indicates a 12-month revenue decline of 18% to $226 million, followed by a 10% recovery in the subsequent year. This trajectory reflects ongoing pressure from the post-pandemic diagnostic market normalization and competitive pricing in core product lines. Risk factors include liquidity constraints and a negative net cash position. Dilution risk is assessed as low, with no recent share issuance and diluted shares matching basic shares at 68.1 million. Adjustments in custom valuations reflect the company's high leverage and negative earnings. Recent 10-K filings highlight supply chain disruptions and regulatory scrutiny of diagnostic pricing. Analysts have issued four "Hold" ratings, with one "Buy" and one "Strong Buy," reflecting uncertainty about the company's ability to restore profitability.